Methylene Blue
Bipolar Disorder
Nova Scotia Health AuthoritySmall moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 73/ 100
Competitive context
67 Active assets in the Bipolar Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Asenapine Dr. Stavroula Rakitzi | Phase 4 | BBB |
Cipralex First Affiliated Hospital of Zhejiang University | Phase 4 | BBB |
LAMOTRIGINE Johns Hopkins University | Phase 4 | BBB |
CITALOPRAM University of Texas Southwestern Medical Center | Phase 4 | BBB |
Seroquel® First Affiliated Hospital of Zhejiang University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Methylene Blue is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →